Rabat – Researchers have successfully reprogrammed blood cells into induced pluripotent stem cells (iPSCs) for the first time in Morocco, the Mohammed VI Foundation for Science and Health announced today.
The foundation explained in a statement that this success will pave the way for creating a national platform for cell reprogramming and differentiation.
Such a platform will support biomedical research, personalized medicine, and the development of new treatments, it stated.
The Director of the Mohammed VI Center for Research and Innovation said this breakthrough indicates the foundation’s commitment to making Morocco a regional leader in medical research and innovation.
Induced pluripotent stem cells are unique because they can grow without limits and turn into almost any type of cell in the body. Scientists can make them from just a small blood sample, which makes them a very powerful tool for medicine and research.
These cells allow scientists to model human diseases using the patient’s own cells, test the safety and effectiveness of new drugs, and develop regenerative treatments to repair vital organs such as the heart, brain, liver, and lungs. They also open new possibilities for immunotherapy against cancers.
iPSCs are already being studied globally in promising clinical trials to treat degenerative diseases, eye disorders, and blood-related conditions.
Since their discovery in Japan in 2006 by Nobel Prize winner Shinya Yamanaka, iPSCs have been used worldwide to model diseases, test new drugs, and explore regenerative treatments for conditions such as Parkinson’s disease, spinal cord injuries, and eye disorders.
Japan leads the field with pioneering clinical trials, while the United States and Europe are advancing in drug testing and personalized medicine. China has also become a major player with investments in stem cell and biotechnology research.
